{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:26Z","timestamp":1781650766845,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jacl.2017.05.016","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T09:17:00Z","timestamp":1496913420000},"page":"986-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2\u00a0years"],"prefix":"10.1016","volume":"11","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Edelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Asset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.05.016_bib1","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.05.016_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11886-015-0582-z","article-title":"Statin intolerance: diagnosis and remedies","volume":"17","author":"Pirillo","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2017.05.016_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","article-title":"Statin intolerance: the clinician's perspective","volume":"17","author":"Stulc","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2017.05.016_bib5","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.05.016_bib7","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2017.05.016_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.05.016_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won't do!","volume":"76","author":"Krahenbuhl","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2017.05.016_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2017.05.016_bib11","doi-asserted-by":"crossref","first-page":"e005402","DOI":"10.1136\/bmjopen-2014-005402","article-title":"Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland","volume":"4","author":"Ruokoniemi","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacl.2017.05.016_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.05.016_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.diabres.2016.07.004","volume":"120","author":"Farmer","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacl.2017.05.016_bib14","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.05.016_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.05.016_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.05.016_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2017.05.016_bib19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib20","unstructured":"Sanofi. Praluent prescribing information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf. Accessed July 19,\u00a02016."},{"key":"10.1016\/j.jacl.2017.05.016_bib21","unstructured":"Sanofi. Praluent summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003882\/WC500194521.pdf. Accessed July 19,\u00a02016."},{"key":"10.1016\/j.jacl.2017.05.016_bib22","unstructured":"Sanofi Genzyme. Press Release. Available at: http:\/\/news.genzyme.com\/press-release\/genzyme-and-isis-announce-fda-approval-kynamro-mipomersen-sodium-injection-treatment-h. Accessed June 22, 2017."},{"key":"10.1016\/j.jacl.2017.05.016_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2017.05.016_bib24","unstructured":"Amgen. Repatha prescribing information. Available at: http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.ashx. Accessed June 22, 2017."},{"key":"10.1016\/j.jacl.2017.05.016_bib25","unstructured":"European Medicines Agency. Repatha: EPAR product information. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003766\/human_med_001890.jsp&mid=WC0b01ac058001d124. Accessed January 31,\u00a02017."},{"key":"10.1016\/j.jacl.2017.05.016_bib26","unstructured":"American College of Preventative Medicine. Medication adherence \u2013 improving health outcomes: a resource from the American College of\u00a0Preventive Medicine. Available at: http:\/\/www.acpm.org\/?MedAdherTT_ClinRef. Accessed July 19,\u00a02016."},{"key":"10.1016\/j.jacl.2017.05.016_bib27","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.clinthera.2015.07.008","article-title":"Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels","volume":"37","author":"Roth","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2017.05.016_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2017.05.016_bib29","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2017.05.016_bib32","first-page":"129","article-title":"Understanding compliance issues for daily self-injectable treatment in ambulatory care settings","volume":"2","author":"Brod","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jacl.2017.05.016_bib33","first-page":"39","article-title":"Patient medication adherence: the forgotten aspect of biologics","volume":"6","author":"Goldberg","year":"2009","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.jacl.2017.05.016_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jacl.2017.05.016_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/VHRM.S102564","article-title":"PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab","volume":"12","author":"Blom","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2017.05.016_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40271-015-0160-x","article-title":"A systematic review of patients' perspectives on the subcutaneous route of medication administration","volume":"9","author":"Ridyard","year":"2016","journal-title":"Patient"},{"key":"10.1016\/j.jacl.2017.05.016_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.05.016_bib38","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II Study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2017.05.016_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.18553\/jmcp.2009.15.6.476","article-title":"Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada","volume":"15","author":"Evans","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jacl.2017.05.016_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1185\/03007995.2011.562494","article-title":"Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population","volume":"27","author":"Kamat","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2017.05.016_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.05.016_bib42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1742-1241.2011.02779.x","article-title":"Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin\/ezetimibe on parameters of insulin resistance","volume":"65","author":"Moutzouri","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2017.05.016_bib43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.05.016_bib44","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar2084","article-title":"Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden","volume":"8","author":"Kristensen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2017.05.016_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/14737175.2014.945523","article-title":"Fostering adherence to injectable disease-modifying therapies in multiple sclerosis","volume":"14","author":"Lugaresi","year":"2014","journal-title":"Expert Rev Neurother"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T08:38:51Z","timestamp":1659083931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417303422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1933287417303422"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.05.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}